MEB-1170 Human Clinical Phase 1 Single Ascending Dose Outcomes
No Drug Related Adverse Events for MEB-1170 at All Doses Tested (20 mg to 400 mg)
Safety Measures
-
-
Vitals: There were no notable trends in changes noted across the dose-range studied.
-
Blood chemistry: There were no notable trends in changes noted across the dose-range studied.
-
Respiratory Depression Measures
-
-
Saturated Oxygen: There were no notable trends of SpO2 changes noted across the dose-range studied.
-
Capnography: There were no notable trends of EtCO2 changes noted across the dose-range studied.
-
Pharmacokinetics
-
-
Achieved desirable exposures of MEB-1170 in humans
-
Dose linear exposures of MEB-1170.
-
Cardiovascular Safety
-
-
No EKG abnormalities across the dose-range studied.
-
Sedation
-
-
None observed for MEB-1170 across the dose-range studied.
-